{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:45:57Z","timestamp":1778453157045,"version":"3.51.4"},"reference-count":23,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,28]]},"DOI":"10.1182\/bloodadvances.2023011030","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T20:57:20Z","timestamp":1711486640000},"page":"2400-2404","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Nivolumab plus brentuximab vedotin for relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d University of Bologna, Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"2Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"2Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"3Humanitas University, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-4207","authenticated-orcid":false,"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"4School of Medicine, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"6Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-6730","authenticated-orcid":false,"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[{"name":"9Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-090X","authenticated-orcid":false,"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[{"name":"10Clinical Hematology Department, Institut Catal\u00e0 d'Oncologia, Hospital Duran i Reynals, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"11Department of Medicine & Oncology, Jewish General Hospital, Montreal, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"David","family":"Cunningham","sequence":"additional","affiliation":[{"name":"12Royal Marsden Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-2843","authenticated-orcid":false,"given":"Silvia","family":"Ferrari","sequence":"additional","affiliation":[{"name":"13Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[{"name":"14Seagen Inc, Bothell, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Krajewski","sequence":"additional","affiliation":[{"name":"15Bristol Myers Squibb, Princeton, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Wen","sequence":"additional","affiliation":[{"name":"15Bristol Myers Squibb, Princeton, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alev","family":"Akyol","sequence":"additional","affiliation":[{"name":"15Bristol Myers Squibb, Princeton, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Crowe","sequence":"additional","affiliation":[{"name":"15Bristol Myers Squibb, Princeton, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"16BC Cancer, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"16","key":"2024052418405088200_bib1","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024052418405088200_bib2","article-title":"Treatment patterns and outcomes of relapsed\/refractory peripheral T-cell lymphoma (RR-PTCL) patients treated in the community oncology setting","volume":"132","author":"Nabhan","year":"2018","journal-title":"Blood"},{"key":"2024052418405088200_bib3","doi-asserted-by":"crossref","first-page":"884091","DOI":"10.3389\/fonc.2022.884091","article-title":"Retrospective analysis of 118 patients with cutaneous T-cell lymphomas: a single-center experience","volume":"12","author":"Polgarova","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"2024052418405088200_bib4","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2024052418405088200_bib5","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2024052418405088200_bib6","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"key":"2024052418405088200_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"23","key":"2024052418405088200_bib8","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024052418405088200_bib9","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024052418405088200_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"2024052418405088200_bib11","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2024052418405088200_bib12","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"issue":"33","key":"2024052418405088200_bib13","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"2024052418405088200_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-137653","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory mediastinal gray zone lymphoma: primary efficacy and safety analysis of the phase 2 CheckMate 436 study","volume":"136","author":"Santoro","year":"2020","journal-title":"Blood"},{"issue":"27","key":"2024052418405088200_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024052418405088200_bib16","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organization for research and treatment of cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024052418405088200_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"2024052418405088200_bib18","doi-asserted-by":"crossref","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"20","key":"2024052418405088200_bib19","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"suppl 16","key":"2024052418405088200_bib20","article-title":"Tislelizumab, a PD-1 inhibitor for relapsed\/refractory mature T\/NK-cell neoplasms: results from a phase 2 study","volume":"40","author":"Bachy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024052418405088200_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"2024052418405088200_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-143252","article-title":"A\u00a0phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2024052418405088200_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2400\/2226414\/blooda_adv-2023-011030-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2400\/2226414\/blooda_adv-2023-011030-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:41:07Z","timestamp":1716576067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/10\/2400\/515499\/Nivolumab-plus-brentuximab-vedotin-for-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011030","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}